Product Name :
Pramipexole dihydrochloride hydrate
Description:
Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson’s disease (PD) and restless legs syndrome (RLS).
CAS:
191217-81-9
Molecular Weight:
302.26
Formula:
C10H21Cl2N3OS
Chemical Name:
(S)-N6-propyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazole-2, 6-diamine dihydrochloride hydrate
Smiles :
O.Cl.Cl.CCCN[C@@H]1CC2SC(N)=NC=2CC1
InChiKey:
APVQOOKHDZVJEX-QTPLPEIMSA-N
InChi :
InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0…/s1
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥12 months if stored properly.
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Pramipexole dihydrochloride hydrate is a selective and blood-brain barrier (BBB) penetrant dopamine D2-type receptor agonist, with Kis of 2.2 nM, 3.9 nM, 0.5 nM and 1.3 nM for D2-type receptor, D2, D3 and D4 receptors, respectively. Pramipexole dihydrochloride hydrate can be used for the research of Parkinson’s disease (PD) and restless legs syndrome (RLS).{{Ontuxizumab} web|{Ontuxizumab} Others|{Ontuxizumab} NF-κB|{Ontuxizumab} Technical Information|{Ontuxizumab} In stock|{Ontuxizumab} manufacturer} |Product information|CAS Number: 191217-81-9|Molecular Weight: 302.{{Lipoxin A4} MedChemExpress|{Lipoxin A4} Interleukin Related|{Lipoxin A4} Protocol|{Lipoxin A4} Purity|{Lipoxin A4} custom synthesis|{Lipoxin A4} Epigenetics} 26|Formula: C10H21Cl2N3OS|Chemical Name: (S)-N6-propyl-4, 5, 6, 7-tetrahydrobenzo[d]thiazole-2, 6-diamine dihydrochloride hydrate|Smiles: O.Cl.Cl.CCCN[C@@H]1CC2SC(N)=NC=2CC1|InChiKey: APVQOOKHDZVJEX-QTPLPEIMSA-N|InChi: InChI=1S/C10H17N3S.2ClH.H2O/c1-2-5-12-7-3-4-8-9(6-7)14-10(11)13-8;;;/h7,12H,2-6H2,1H3,(H2,11,13);2*1H;1H2/t7-;;;/m0…/s1|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.PMID:24733396 |Shelf Life: ≥12 months if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|How to use|In Vitro:|Pramipexole dihydrochloride hydrate shows a low binding affinity for D1-type receptor, with an IC50 of >50,000 nM. Pramipexole dihydrochloride hydrate (0.01-10 μM; 72 hours) produces dose-dependent increases of dendritic arborization and soma size. Pramipexole dihydrochloride hydrate attenuates levodopa-induced toxicity in mesencephalic cultures.|In Vivo:|Pramipexole dihydrochloride hydrate (0.25-1 mg/kg; i.p.) significantly reduces the infarction volume in animals. Pramipexole dihydrochloride hydrate improves neurological recovery. Pramipexole dihydrochloride hydrate prevents ischemic cell death via mitochondrial pathways in ischemic stroke.|Products are for research use only. Not for human use.|